Cardiovascular Risk Factors and Peripheral Arterial Disease

  • Stella S. Daskalopoulou
  • Dimitri P. Mikhailidis
Chapter

References

  1. 1.
    Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;252:207–74.CrossRefPubMedGoogle Scholar
  2. 2.
    Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung and Blood Institute scientific statement. Circulation. 2005;112:2735–52.CrossRefPubMedGoogle Scholar
  3. 3.
    Alberti KG, Eckel RH, Grundy SM, International Diabetes Federation Task Force on Epidemiology and Prevention. Hational Heart, Lung, and Blood Institute. American Heart Association; World Heart Federation. International Atherosclerosis Society; International Association for the Study of Obesity, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention. National Heart, Lung, and Blood Institute. American Heart Association. World Heart Federation. International Atherosclerosis Society. and International Association for the Study of Obesity. Circulation. 2009;120:1640–5.CrossRefPubMedGoogle Scholar
  4. 4.
    Cannon CP, Blazing MA, Giugliano RP, IMPROVE-IT Investigators, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–97.CrossRefPubMedGoogle Scholar
  5. 5.
    Colhoun HM, Betteridge DJ, Durrington PN, CARDS investigators, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–96.CrossRefPubMedGoogle Scholar
  6. 6.
    Daskalopoulou SS, Daskalopoulos ME, Liapis CD, Mikhailidis DP. Peripheral arterial disease: a missed opportunity to administer statins so as to reduce cardiac morbidity and mortality. Curr Med Chem. 2005;12:443–52.CrossRefPubMedGoogle Scholar
  7. 7.
    Kolovou GD, Mikhailidis DP, Kovar J, Lairon D, Nordestgaard BG, Ooi TC, Perez-Martinez P, Bilianou H, Anagnostopoulou K, Panotopoulos G. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol. 2011;9:258–70.CrossRefPubMedGoogle Scholar
  8. 8.
    Kolovou GD, Mikhailidis DP, Nordestgaard BG, Bilianou H, Panotopoulos G. Definition of postprandial lipaemia. Curr Vasc Pharmacol. 2011;9:292–301.CrossRefPubMedGoogle Scholar
  9. 9.
    Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. High-density lipoprotein, vascular risk, cancer and infection: a case of quantity and quality? Curr Med Chem. 2014;21:2917–26.CrossRefPubMedGoogle Scholar
  10. 10.
    Anastasius M, Kockx M, Jessup W, Sullivan D, Rye KA, Kritharides L. Cholesterol efflux capacity: an introduction for clinicians. Am Heart J. 2016;180:54–63.CrossRefPubMedGoogle Scholar
  11. 11.
    Rizos CV, Elisaf MS, Liberopoulos EN. Effects of thyroid dysfunction on lipid profile. Open Cardiovasc Med J. 2011;5:76–84.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;253:281–344.CrossRefPubMedGoogle Scholar
  13. 13.
    Jellinger PS, Handelsman Y, Rosenblit PD, et al. American association of clinical endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23(Suppl 2):1–87.CrossRefPubMedGoogle Scholar
  14. 14.
    American Diabetes Association. Cardiovascular disease and risk management. Sec. 9. In standards of medical care in diabetes 2017. Diabetes Care. 2017;40(Suppl. 1):S75–87.CrossRefGoogle Scholar
  15. 15.
    Katsiki N, Nikolic D, Montalto G, Banach M, Mikhailidis DP, Rizzo M. The role of fibrate treatment in dyslipidemia: an overview. Curr Pharm Des. 2013;19:3124–31.CrossRefPubMedGoogle Scholar
  16. 16.
    Alnaeb ME, Youssef F, Mikhailidis DP, Hamilton G. Short-term lipid-lowering treatment with atorvastatin improves renal function but not renal blood flow indices in patients with peripheral arterial disease. Angiology. 2006;57:65–71.CrossRefPubMedGoogle Scholar
  17. 17.
    De Backer G, Ambrosioni E, Borch-Johnsen K, et al. Third Joint Task Force of European and Other Societies on cardiovascular disease prevention in clinical practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2003;24:1601–10.CrossRefPubMedGoogle Scholar
  18. 18.
    Giannopoulos A, Kakkos S, Abbott A, Naylor AR, Richards T, Mikhailidis DP, Geroulakos G, Nicolaides AN. Long-term mortality in patients with asymptomatic carotid stenosis: implications for statin therapy. Eur J Vasc Endovasc Surg. 2015;50:573–82.CrossRefPubMedGoogle Scholar
  19. 19.
    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.CrossRefGoogle Scholar
  20. 20.
    Tsiara S, Elisaf M, Mikhailidis DP. Influence of smoking on predictors of vascular disease. Angiology. 2003;54:507–30.CrossRefPubMedGoogle Scholar
  21. 21.
    Cheshire NJW, Wolfe JHN, Barradas MA, Chambler AW, Mikhailidis DP. Smoking and plasma fibrinogen, lipoprotein (a) and serotonin are markers for postoperative infrainguinal graft stenosis. Eur J Vasc Endovasc Surg. 1996;11:479–86.CrossRefPubMedGoogle Scholar
  22. 22.
    Katsiki N, Papadopoulou SK, Fachantidou AI, Mikhailidis DP. Smoking and vascular risk: are all forms of smoking harmful to all types of vascular disease? Public Health. 2013;127:435–41.CrossRefPubMedGoogle Scholar
  23. 23.
    Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e726–79.CrossRefPubMedGoogle Scholar
  24. 24.
    Robless P, Mikhailidis DP, Stansby G. Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg. 2001;88:787–800.CrossRefPubMedGoogle Scholar
  25. 25.
    CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348:1329–39.CrossRefGoogle Scholar
  26. 26.
    Klonaris C, Patelis N, Drebes A, Matheiken S, Liakakos T. Antiplatelet treatment in peripheral arterial disease: the role of novel antiplatelet agents. Curr Pharm Des. 2016;22:4610–6.CrossRefPubMedGoogle Scholar
  27. 27.
    Hiatt WR, Fowkes FG, Heizer G, EUCLID Trial Steering Committee and Investigators, et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med. 2017;376:32–40.CrossRefPubMedGoogle Scholar
  28. 28.
    Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69:692–711.CrossRefPubMedGoogle Scholar
  29. 29.
    Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.CrossRefPubMedGoogle Scholar
  30. 30.
    Ridker PM, Cannon CP, Morrow D, et al. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Rahman M, Brown CD, Coresh J, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group, et al. The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular disease: a report from the antihypertensive and lipid-lowering treatment to prevent Heart Attack Trial. Arch Intern Med. 2003;164:969–76.CrossRefGoogle Scholar
  32. 32.
    Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol. 2004;57:728–34.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Daskalopoulou SS, Athyros VG, Elisaf M, Mikhailidis DP. Uric acid levels and vascular disease. Curr Med Res Opin. 2004;20:951–4.CrossRefPubMedGoogle Scholar
  34. 34.
    Sabatine MS, Giugliano RP, Keech AC, FOURIER Steering Committee and Investigators, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Stella S. Daskalopoulou
    • 1
  • Dimitri P. Mikhailidis
    • 2
  1. 1.Faculty of Medicine, Divisions of Internal Medicine and Experimental Medicine, Department of MedicineMcGill UniversityMontrealCanada
  2. 2.Department of Clinical BiochemistryRoyal Free Hospital Campus, University College London Medical School, University College LondonLondonUK

Personalised recommendations